ebbinghaus

PCSK9 inhibition and neurocognitive effects:Weighing up the evidence

Whether lowering LDL cholesterol levels has detrimental effects on cognitive function has long been a concern with statins (1). Recently, attention has also focused on the PCSK9 inhibitors.  Professor François Mach (Geneva University Hospitals, Switzerland) discusses what is known from the latest trials. Evidence from…

Prof Robert Rosenson: REGARDS study adds to EBBINGHAUS reassures on lack of effect on neurocognition at low LDL-C

In a new report today, Professor Robert Rosenson (Mount Sinai Icahn School of Medicine, Mount Sinai Hospita, New York, USA) discusses results from the REGARDS study. This study investigated whether there was any link between PCSK9 genetic variants associated with low LDL cholesterol and cognitive…

EBBINGHAUS counters claim of neurocognitive effects with PCSK9 inhibition

Ebbinghaus was a pioneer of memory research. One of his key contributions was the forgetting curve, which describes the exponential loss of learned information. It is therefore fitting that a trial bearing his name has shown that very low LDL cholesterol levels on PCSK9 monoclonal…

Prof Francois Mach discusses EBBINGHAUS

Low LDL-C, PCSK9 and dementia risk?

An ongoing debate among the experts is whether the very low levels of LDL cholesterol with PCSK9 inhibitor treatment might be associated with neurocognitive events. In fact, the debate predates the PCSK9 inhibitors, with statins linked with cognitive impairment (1-4). However, when the statin data…